14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
HOLX vs RMD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, ResMed Inc. (RMD) is the stronger overall head-to-head candidate over Hologic Inc (HOLX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HOLX carries a Unified Composite Score of 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin), whereas RMD carries 61.9/100 (BUY) at $235.63 (19.5x Forward P/E, 34.0% operating margin).
Composite vs. Pillar Nuance: While HOLX currently prints a higher short-term Unified Composite Score (64.2/100 BUY vs. RMD 61.9/100 BUY), RMD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 23.0% operating margin) and revenue trajectory (+5.9% vs. +2.5% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HOLX vs RMD. Trailing 12-month operating profitability (HOLX 23.0% vs RMD 34.0%) and valuation multiples (HOLX 20.1x vs RMD 19.5x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Instruments & Supplies value chain with $16.9B market capitalization and 23.0% operating margin.
OpEx & R&D Reinvestment37.4% of Rev ($1.54B)
90D Engineering Disclosures0 Published
RMD Moat ProfileHigh-Margin Pricing Power Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $33.3B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment27.8% of Rev ($1.59B)
90D Engineering Disclosures0 Published
Investor FAQ HOLX vs RMD Key Questions & Quantitative Answers
As of Nov 20, 2026, ResMed Inc. (RMD) is the stronger overall head-to-head candidate over Hologic Inc (HOLX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HOLX carries a Unified Composite Score of 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin), whereas RMD carries 61.9/100 (BUY) at $235.63 (19.5x Forward P/E, 34.0% operating margin). Composite vs. Pillar Nuance: While HOLX currently prints a higher short-term Unified Composite Score (64.2/100 BUY vs. RMD 61.9/100 BUY), RMD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 23.0% operating margin) and revenue trajectory (+5.9% vs. +2.5% YoY).
RMD leads the Growth & Scale pillar: HOLX posts +2.5% YoY revenue growth and -9.2% YoY earnings growth on $4.13B TTM revenue (60.4% gross margin, 23.0% operating margin), compared with RMD at +5.9% YoY revenue growth and +23.2% YoY earnings growth on $5.73B TTM revenue (61.8% gross margin, 34.0% operating margin). On trailing 12-month operating scale, HOLX generates $4.13B in USD-normalized revenue versus $5.73B for RMD. In operating R&D and SG&A reinvestment, HOLX deploys 37.4% of Rev ($1.54B) (0 90-day corporate R&D disclosures) versus 27.8% of Rev ($1.59B) (0 disclosures) for RMD.
RMD screens cheaper on headline valuation multiples. HOLX trades at 20.1x Forward P/E, 31.4x Trailing P/E, 1.66x PEG, and 4.1x EV/Revenue (32.7% EBITDA margin), whereas RMD trades at 19.5x Forward P/E, 21.6x Trailing P/E, 1.30x PEG, and 5.7x EV/Revenue (27.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HOLX (10.9% ROE) versus RMD (26.4% ROE) capital efficiency.
In options market volatility and institutional positioning, HOLX carries 6.3% implied volatility (3rd %ile, Compressed (<25th %ile)), a 6.20x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.08β · 3% Vol realized risk). By comparison, RMD carries 90.6% implied volatility (100th %ile, Extreme (>80th %ile)), a 4.01x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.39β · 41% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.